Intravenous immunoglobulin therapy for autoimmune diseases

References

• Seite JF, Shoenfeld Y, Youinou P, Hillion S. What is the contents of the magic draft IVIg?. Autoimmun Rev. 2008; 7435–439.
   PubMed Web of Science ®Google Scholar
• Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med. 1982; 3061254–1258.
   PubMed Web of Science ®Google Scholar
• Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet. 1983; 2193–195.
   PubMed Web of Science ®Google Scholar
• Kimberly RP, Salmon JE, Bussel JB, Crow MK, Hilgartner MW. Modulation of mononuclear phagocyte function by intravenous gamma-globulin. J Immunol. 1984; 132745–750.
   PubMed Web of Science ®Google Scholar
• Bruhns P. Colony-timulating factor-1-dependant macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity. 2003; 18581.
   Google Scholar
• Mollnes T. Higa-dose intravenous immunoglobulin treatment activates complament in vivo. Scand J Immunol. 1998312–317.
   PubMedGoogle Scholar
• Basta M. F(ab)’2- mediated neutralization of C3a C5a anaphylactoxins: a novel effector function of immunoglobulins. Nat Med.. 2003431–438.
   PubMedGoogle Scholar
• Klaesson S, Ringden O, Markling L, Remberger M, Lundkvist I. Immune modulatory effects of immunoglobulins on cell-mediated immune responses in vitro. Scand J Immunol. 1993; 38477–484.
   PubMedGoogle Scholar
• Rossi F, Kazatchkine MD. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol. 1989; 1434104–4109.
   PubMed Web of Science ®Google Scholar
• Adib M, Ragimbeau J, Avrameas S, Ternynck T. IgG autoantibody activity in normal mouse serum is controlled by IgM. J Immunol. 1990; 1453807–3813.
   PubMed Web of Science ®Google Scholar
• Seite JF, Shoenfeld Y, Youinou P, Hillion S. What is the contents of the magic draft IVIg?. Autoimmun Rev. 2008; 7435–439.
   PubMed Web of Science ®Google Scholar
• Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE. Anti-idiotypic suppression of autoantibodies to factor VIII [antihaemophilic factor] by high-dose intravenous gammaglobulin. Lancet. 1984; 2765–768.
   PubMed Web of Science ®Google Scholar
• Kazatchkine MD, Lacroix-Desmazes S, Moreau A, Kaveri SV. Idiotypic regulation of anti-factor VIII antibodies. Haematologica. 2000; 8597–99.
   PubMedGoogle Scholar
• Krause I, Blank M, Shoenfeld Y. Anti-DNA and anti phospholipid antibodies in IVIG preperations: in vivo study in naive mice. J Clin Immunol. 1988; 1852–60.
   Google Scholar
• Rossi F, Kazatchkine MD. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol. 1989; 1434104–4109.
   PubMed Web of Science ®Google Scholar
• Rossi F, Jayne DR, Lockwood CM, Kazatchkine MD. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol. 1991; 83298–303.
   PubMed Web of Science ®Google Scholar
• Tandon N, Jayne DR, McGregor AM, Weetman AP. Analysis of anti-idiotypic antibodies against anti-microsomal antibodies in patients with thyroid autoimmunity. J Autoimmun. 1992; 5557–570.
   PubMed Web of Science ®Google Scholar
• Lundkvist I, van Doorn PA, Vermeulen M, Brand A. Spontaneous recovery from the Guillain–Barre syndrome is associated with anti-idiotypic antibodies recognizing a cross-reactive idiotype on anti-neuroblastoma cell line antibodies. Clin Immunol Immunopathol. 1993; 67192–198.
   PubMedGoogle Scholar
• Caccavo D, Vaccaro F, Ferri GM, Amoroso A, Bonomo L. Anti-idiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use. J Autoimmun. 1994; 7537–548.
   PubMedGoogle Scholar
• Mehta YS, Badakere SS. In-vitro inhibition of antiplatelet autoantibodies by intravenous immunoglobulins and Rh immunoglobulins. J Postgrad Med. 1996; 4246–49.
   PubMedGoogle Scholar
• DeKeyser F, DeKeyser H, Kazatchkine MD, Rossi F, Dang H, Talal N. Pooled human immunoglobulins contain anti-idiotypes with reactivity against the SLE-associated 4B4 cross-reactive idiotype. Clin Exp Rheumatol. 1996; 14587–591.
   PubMedGoogle Scholar
• Yuki N, Miyagi F. Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies. J Neurol Sci. 1996; 139160–162.
   PubMed Web of Science ®Google Scholar
• Sherer Y, Wu R, Kraus I, Peter JB, Shoenfeld Y. Antiphospholipid antibody levels in intravenous immunoglobulin [IVIg] preparations. Lupus. 2001; 10569–570.
   Google Scholar
• Silvestris F, Cafforio P, Dammacco F. Pathogenic anti-DNA idiotype-reactive IgG in intravenous immunoglobulin preparations. Clin Exp Immunol. 1994; 9719–25.
   PubMed Web of Science ®Google Scholar
• Svenson M, Hansen MB, Ross C, Diamant M, Rieneck K, Nielsen H, . Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood. 1998; 912054–2061.
   PubMed Web of Science ®Google Scholar
• Le PL, Bendaoud B, Dueymes M, Daridon C, Youinou P, Shoenfeld Y, . BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer. J Clin Immunol. 2007; 27257–265.
   PubMedGoogle Scholar
• Le PL, Sapir T, Bendaoud B, Youinou P, Shoenfeld Y, Pers JO. Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann N Y Acad Sci. 2007; 1110426–432.
   PubMedGoogle Scholar
• El-Shanawany Jolles S. Intravenous immunoglobulins and autoimmune disease. Ann N Y Acad Sci. 2007; 11507–515.
   Google Scholar
• Bussel J, . Intravenous gammaglobulin treatment for chronic idiopathic thrombocytopenic purpura. Blood. 1983; 62480–486.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006; 313670–673.
   PubMed Web of Science ®Google Scholar
• Lemieux R, Bazin R, Neron S. Therapeutic intravenous immunoglobulins. Mol Immunol. 2005; 42839–848.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med. 1997; 126721–730.
   PubMed Web of Science ®Google Scholar
• Hooper JA. Intravenous Immunoglobulins: Evolution of Commercial IVIG Preparations. Immunol Allergy Clin North Am. 2008; 28765–778.
   PubMed Web of Science ®Google Scholar
• Katz U, Kishner I, Magalashvili D, Shoenfeld Y, Achiron A. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience. Autoimmunity. 2006; 39 6: 513–517.
   PubMed Web of Science ®Google Scholar
• Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005; 29173–184.
   PubMed Web of Science ®Google Scholar
• Elkayam O, Paran D, Milo R, Davidovitz Y, Moznino-Sarafian D, Zeltser D, . Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases. Ann Rheum Dis. 2000; 5977–80.
   PubMedGoogle Scholar
• Sherer Y, Shoenfeld Y. Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus. Autoimmun Rev. 2006; 5153–155.
   PubMedGoogle Scholar
• Maier WP, Gordon DS, Howard RF, Saleh MN, Miller SB, Lieberman JD, . Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. Arthritis Rheum. 1990; 331233–1239.
   PubMed Web of Science ®Google Scholar
• Sherer Y, Langevitz P, Levy Y, Fabrizzi F, Shoenfeld Y. Treatment of chronic bilateral pleural effusions with intravenous immunoglobulin and cyclosporin. Lupus. 1999; 8324–327.
   PubMedGoogle Scholar
• Sherer Y, Levy Y, Langevitz P, Lorber M, Fabrizzi F, Shoenfeld Y. Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin Rheumatol. 1999; 18170–173.
   PubMed Web of Science ®Google Scholar
• Aharon A, Levy Y, Bar-Dayan Y, Afek A, Zandman-Goddard G, Skurnik Y, . Successful treatment of early secondary myelofibrosis in SLE with IVIG. Lupus. 1997; 6408–411.
   PubMed Web of Science ®Google Scholar
• De Pita O, Bellucci AM, Ruffelli M, Girardelli CR, Puddu P. Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus. Lupus. 1997; 6415–417.
   PubMed Web of Science ®Google Scholar
• Puddu P, De Pita O, Ruffelli M, Bellucci AM, Girardelli CR, Galeazzi M, . Intravenous immunoglobulin therapy: modification of the immunofluorescence pattern in the skin of six patients with systemic lupus erythematosus. Arthritis Rheum. 1996; 39704–705.
   PubMedGoogle Scholar
• Goodfield M, Davison K, Bowden K. Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat. 2004; 1546–50.
   PubMedGoogle Scholar
• Sherer Y, Levy Y, Langevitz P, Rauova L, Fabrizzi F, Shoenfeld Y. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology. 2001; 62133–137.
   PubMed Web of Science ®Google Scholar
• Akashi K, Nagasawa K, Mayumi T, Yokota E, Oochi N, Kusaba T. Successful treatment of refractory systemic lupus erythematosus with intravenous immunoglobulins. J Rheumatol. 1990; 17375–379.
   PubMed Web of Science ®Google Scholar
• Becker BN, Fuchs H, Hakim R. Intravenous immune globulin in the treatment of patients with systemic lupus erythematosus and end-stage renal disease. J Am Soc Nephrol. 1995; 51746–1750.
   PubMedGoogle Scholar
• Boletis JN, Ioannidis JP, Boki KA, Moutsopoulos HM. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet. 1999; 354569–570.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med. 1997; 126721–730.
   PubMed Web of Science ®Google Scholar
• Said PB, Martinuzzo ME, Carreras LO. Neutralization of lupus anticoagulant activity by human immunoglobulin “in vitro”. Nouv Rev Fr Hematol. 1992; 3437–42.
   PubMedGoogle Scholar
• Galli M, Cortelazzo S, Barbui T. In vivo efficacy of intravenous gammaglobulins in patients with lupus anticoagulant is not mediated by anti-idiotypic mechagnism. J Hematol. 1991; 38184–188.
   Google Scholar
• Krause I, Blank M, Kopolovic J, Afek A, Goldberg I, Tomer Y, . Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. J Rheumatol. 1995; 221068–1074.
   PubMed Web of Science ®Google Scholar
• Bakimer R, Guilburd B, Zurgil N, Shoenfeld Y. The effect of intravenous gamma-globulin on the induction of experimental antiphospholipid syndrome. Clin Immunol Immunopathol. 1993; 6997–102.
   PubMedGoogle Scholar
• Jerzak M, Rechberger T, Gorski A. Intravenous immunoglobulin therapy influences T cell adhesion to extracellular matrix in women with a history of recurrent spontaneous abortions. Am J Reprod Immunol. 2000; 44336–341.
   PubMedGoogle Scholar
• Carreras LD, Perez GN, Vega HR, Casavilla F. Lupus anticoagulant and recurrent fetal loss: successful treatment with gammaglobulin. Lancet. 1988; 2393–394.
   PubMed Web of Science ®Google Scholar
• Sherer Y, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology (Oxford). 2000; 39421–426.
   PubMed Web of Science ®Google Scholar
• Tincani A, Scarsi M, Franceschini F, Cattaneo R. Intravenous immunoglobulin in pregnancy: a chance for patients with an autoimmune disease. Isr Med Assoc J. 2007; 9553–554.
   PubMedGoogle Scholar
• Sher G, Matzner W, Feiman F. A rational basis for the use of aspirin∖heparin and IVIG immunotherapy in the treatment of recurrent IVF failure associated with antiphospholipid antibodies. Am J Reprod Immunol. 1998; 39391–394.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, . A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993; 3291993–2000.
   PubMed Web of Science ®Google Scholar
• Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, . Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthr Rheum. 2002; 46467–474.
   PubMed Web of Science ®Google Scholar
• Cherin P, Piette JC, Wechsler B, Bletry O, Ziza JM, Laraki R, . Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol. 1994; 211092–1097.
   PubMed Web of Science ®Google Scholar
• Lassmann H. Multiple sclerosis pathology: evolution of pathogenetic concepts. Brain Pathol. 2005; 15217–222.
   PubMed Web of Science ®Google Scholar
• Rizvi SA, Agius MA. Current approved options for treating patients with multiple sclerosis. Neurology. 2004; 63S8–14.
   PubMed Web of Science ®Google Scholar
• Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet. 1997; 349589–593.
   PubMed Web of Science ®Google Scholar
• Gray O, McDonnell GV, Forbes RB. Intravenous immunoglobulins for multiple sclerosis. Cochrane Database Syst Rev. 2003CD002936.
   Google Scholar
• Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain–Barre syndrome. Neurology. 1996; 46100–103.
   PubMed Web of Science ®Google Scholar
• van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain–Barre syndrome. Dutch Guillain–Barre Study Group. N Engl J Med. 1992; 3261123–1129.
   PubMed Web of Science ®Google Scholar
• , Plasma Exchange/Sandoglobulin Guillain–Barre Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain–Barre syndrome. Lancet. 1997; 349225–230.
   PubMed Web of Science ®Google Scholar
• Van SI, Winer JB, De HR, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2002CD001797.
   Google Scholar
• Hughes R, Bensa S, Willison H, Van den BP, Comi G, Illa I, . Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001; 50195–201.
   PubMed Web of Science ®Google Scholar
• van SI, van den Berg LH, de HR, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev. 2005CD004429.
   Google Scholar
• Levy Y, Uziel Y, Zandman GG, Amital H, Sherer Y, Langevitz P, . Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Ann Rheum Dis. 2003; 621221–1223.
   PubMed Web of Science ®Google Scholar
• Levy Y, Uziel Y, Zandman G, Rotman P, Amital H, Sherer Y, . Response of vasculitic peripheral neuropathy to intravenous immunoglobulin. Ann NY Acad Sci. 2005; 1051779–786.
   PubMed Web of Science ®Google Scholar
• Zinman L, Bril V. IVIG Treatment for Myasthenia Gravis: Effectiveness, limitations, and novel therapeutic strategies. Ann NY Acad Sci. 2008; 1132264–270.
   PubMedGoogle Scholar
• Linker RA, Gold R. Use of intravenous immunoglobulin and plasma exchange in neurological disease. Curr Opin Neurol. 2008; 21358–365.
   PubMedGoogle Scholar
• Mimouni D, Blank M, Ashkenazi L, Milner Y, Frusic-Zlotkin M, Anhalt GJ, . Protective effect of intravenous immunoglobulin [IVIG] in an experimental model of pemphigus vulgaris. Clin Exp Immunol. 2005; 142426–432.
   PubMed Web of Science ®Google Scholar
• Sami N, Qureshi A, Ruocco E, Ahmed AR. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol. 2002; 1381158–1162.
   PubMed Web of Science ®Google Scholar
• Sami N, Bhol KC, Ahmed RA. Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris. Eur J Dermatol. 2003; 13377–381.
   PubMedGoogle Scholar